What is a stock summary page? Click here for an overview.
Business Description
Takara Bio Inc
ISIN : JP3460200003
Share Class Description:
TSE:4974: Ordinary SharesDescription
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 29.65 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.18 | |||||
| Interest Coverage | 59.65 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 6.89 | |||||
| Beneish M-Score | -2.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -1.9 | |||||
| 3-Year EBITDA Growth Rate | -23.1 | |||||
| 3-Year EPS without NRI Growth Rate | -42.4 | |||||
| 3-Year Book Growth Rate | 14.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 23.51 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 6.17 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.53 | |||||
| 9-Day RSI | 23.7 | |||||
| 14-Day RSI | 25.17 | |||||
| 3-1 Month Momentum % | -17.33 | |||||
| 6-1 Month Momentum % | -22.07 | |||||
| 12-1 Month Momentum % | -13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.78 | |||||
| Quick Ratio | 4.94 | |||||
| Cash Ratio | 3.64 | |||||
| Days Inventory | 270.21 | |||||
| Days Sales Outstanding | 76.2 | |||||
| Days Payable | 47.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 4.56 | |||||
| Dividend Payout Ratio | 5.06 | |||||
| 3-Year Dividend Growth Rate | 23.6 | |||||
| Forward Dividend Yield % | 4.56 | |||||
| 5-Year Yield-on-Cost % | 21.85 | |||||
| Shareholder Yield % | 4.37 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 58.62 | |||||
| Operating Margin % | 2.77 | |||||
| Net Margin % | -0.12 | |||||
| FCF Margin % | -9.52 | |||||
| ROE % | -0.05 | |||||
| ROA % | -0.04 | |||||
| ROIC % | -0.02 | |||||
| 3-Year ROIIC % | -31.09 | |||||
| ROC (Joel Greenblatt) % | 1.42 | |||||
| ROCE % | 0.86 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 21.42 | |||||
| PE Ratio without NRI | 233.36 | |||||
| Shiller PE Ratio | 14.42 | |||||
| PEG Ratio | 24.06 | |||||
| PS Ratio | 2.19 | |||||
| PB Ratio | 0.86 | |||||
| Price-to-Tangible-Book | 0.86 | |||||
| Price-to-Operating-Cash-Flow | 15.43 | |||||
| EV-to-EBIT | 53.64 | |||||
| EV-to-EBITDA | 9.92 | |||||
| EV-to-Revenue | 1.24 | |||||
| EV-to-FCF | -14.52 | |||||
| Price-to-GF-Value | 0.67 | |||||
| Price-to-Projected-FCF | 0.8 | |||||
| Price-to-DCF (Earnings Based) | 5.12 | |||||
| Price-to-Median-PS-Value | 0.33 | |||||
| Price-to-Graham-Number | 2.87 | |||||
| Price-to-Net-Current-Asset-Value | 2.04 | |||||
| Price-to-Net-Cash | 4.82 | |||||
| Earnings Yield (Greenblatt) % | 1.86 | |||||
| FCF Yield % | -4.71 | |||||
| Forward Rate of Return (Yacktman) % | -5.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Takara Bio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 43,053 | ||
| EPS (TTM) (円) | -0.438 | ||
| Beta | 0.3 | ||
| 3-Year Sharpe Ratio | -1.18 | ||
| 3-Year Sortino Ratio | -1.24 | ||
| Volatility % | 24.38 | ||
| 14-Day RSI | 25.17 | ||
| 14-Day ATR (円) | 23.889682 | ||
| 20-Day SMA (円) | 822.6 | ||
| 12-1 Month Momentum % | -13 | ||
| 52-Week Range (円) | 711 - 1186 | ||
| Shares Outstanding (Mil) | 120.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Takara Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Takara Bio Inc Stock Events
| Event | Date | Price (円) | ||
|---|---|---|---|---|
| No Event Data | ||||
Takara Bio Inc Frequently Asked Questions
What is Takara Bio Inc(TSE:4974)'s stock price today?
The current price of TSE:4974 is 円724.00. The 52 week high of TSE:4974 is 円1186.00 and 52 week low is 円711.00.
When is next earnings date of Takara Bio Inc(TSE:4974)?
The next earnings date of Takara Bio Inc(TSE:4974) is .
Does Takara Bio Inc(TSE:4974) pay dividends? If so, how much?
The Dividend Yield %  of Takara Bio Inc(TSE:4974) is 4.56% (As of Today), Highest Dividend Payout Ratio of Takara Bio Inc(TSE:4974) was 5.06. The lowest was 0.11. And the median was 0.2. The  Forward Dividend Yield % of Takara Bio Inc(TSE:4974) is 4.56%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers